Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 165
- Registration Number
- NCT00576667
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 89
- Registration Number
- NCT00577148
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
Extension to Study HMR1964A/3011 in Belgium
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2008-01-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT00576862
- Locations
- 🇧🇪
Sanofi-Aventis, Brussels, Belgium
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2008-01-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4464
- Registration Number
- NCT00576368
- Locations
- 🇧🇪
Sanofi-Aventis, Brussels, Belgium
Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT00576823
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
🇸🇬Sanofi-Aventis Aministrative Office, Singapore, Singapore
Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
- Conditions
- Prostatic Diseases
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT00575913
- Locations
- 🇹🇭
Sanofi-Aventis, Bangkok, Thailand
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Neoplasm
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 546
- Registration Number
- NCT00574275
- Locations
- 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland
Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions
- Conditions
- Peripheral Vascular Diseases
- Interventions
- Biological: riferminogene pecaplasmidBiological: Placebo (for riferminogene pecaplasmid)
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 525
- Registration Number
- NCT00566657
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
- Conditions
- Nasopharyngeal NeoplasmsCarcinoma
- Interventions
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 75
- Registration Number
- NCT00565448
- Locations
- 🇲🇦
Investigational Site Number 504003, Rabat, Morocco
🇵🇭Investigational Site Number 608002, Quezon City, Philippines
🇧🇷Investigational Site Number 076002, Rio De Janeiro, Brazil
Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 124
- Registration Number
- NCT00565162
- Locations
- 🇬🇧
Sanofi-Aventis, Leicester, United Kingdom